BCAL Diagnostics (ASX:BDX) Debt-to-Asset : 0.18 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Debt-to-Asset?

BCAL Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.36 Mil. BCAL Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.14 Mil. BCAL Diagnostics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$8.42 Mil. BCAL Diagnostics's debt to asset for the quarter that ended in Dec. 2023 was 0.18.

BCAL Diagnostics Debt-to-Asset Historical Data

The historical data trend for BCAL Diagnostics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Debt-to-Asset Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Debt-to-Asset

0.13

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	0.13	0.18

Competitive Comparison of BCAL Diagnostics's Debt-to-Asset

For the Diagnostics & Research subindustry, BCAL Diagnostics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Debt-to-Asset falls into.

BCAL Diagnostics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BCAL Diagnostics's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.165	+	0.897)	/	8.371
	=	0.13

BCAL Diagnostics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.364	+	1.139)	/	8.422
	=	0.18

BCAL Diagnostics (ASX:BDX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BCAL Diagnostics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.